Dehydroepiandrosterone inhibits the amplification of glucocorticoid action in adipose tissue

American Journal of Physiology - Endocrinology and Metabolism

Volumn 288, Issue 5 51-5, 2005, Pages

  Apostolova, Galina ^a   Schweizer, Roberto A S ^a   Balazs, Zoltan ^a   Kostadinova, Radina M ^a   Odermatt, Alex ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

11 hydroxysteroid dehydrogenase; Adipocyte; Diabetes; Obesity

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; CCAAT ENHANCER BINDING PROTEIN; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; LEPTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PRASTERONE; ROSIGLITAZONE;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; ENZYME ACTIVITY; GENE AMPLIFICATION; GENETIC TRANSCRIPTION; INSULIN SENSITIVITY; METABOLIC REGULATION; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; RISK BENEFIT ANALYSIS;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; 3T3-L1 CELLS; ADIPOSE TISSUE; ANIMALS; DEHYDROEPIANDROSTERONE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; GLUCOCORTICOIDS; LIVER; MALE; MICE; MICE, INBRED C57BL; THIAZOLIDINEDIONES;

EID: 17444391240     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00442.2004     Document Type: Article

References (60)

1. Alberts P, Engblom L, Edling N, Forsgren M, Klingstrom G, Larsson C, Ronquist-Nii Y, Ohman B, and Abrahmsen L. Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia 45: 1528-1532, 2002.
2. Alberts P, Nilsson C, Selen G, Engblom LO, Edling NH, Norling S, Klingstrom G, Larsson C, Forsgren M, Ashkzari M, Nilsson CE, Fiedler M, Bergqvist E, Ohman B, Bjorkstrand E, and Abrahmsen LB. Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology 144: 4755-4762, 2003.
3. Andrews RC, Rooyackers O, and Walker BR. Effects of the 11β-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab 88: 285-291, 2003.
4. Atanasov AG, Nashev LG, Schweizer RA, Frick C, and Odermatt A. Hexose-6-phosphate dehydrogenase determines the reaction direction of 11β-hydroxysteroid dehydrogenase type 1 as an oxoreductase. FEBS Lett 571: 129-133, 2004.
5. Banhegyi G, Benedetti A, Fulceri R, and Senesi S. Cooperativity between 11β-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase in the lumen of the endoplasmic reticulum. J Biol Chem 279: 27017-27021, 2004.
6. Barf T, Vallgarda J, Emond R, Haggstrom C, Kurz G, Nygren A, Larwood V, Mosialou E, Axelsson K, Olsson R, Engblom L, Edling N, Ronquist-Nii Y, Ohman B, Alberts P, and Abrahmsen L. Arylsulfon-amidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11β-hydroxysteroid dehydrogenase type 1. J Med Chem 45: 3813-3815, 2002.
7. Berger J, Tanen M, Elbrecht A, Hermanowski-Vosatka A, Moller DE, Wright SD, and Thieringer R. Peroxisome proliferator-activated receptor-γ ligands inhibit adipocyte 11β-hydroxysteroid dehydrogenase type 1 expression and activity. J Biol Chem 276: 12629-12635, 2001.
8. Couillard C, Gagnon J, Bergeron J, Leon AS, Rao DC, Skinner JS, Wilmore JH, Despres JP, and Bouchard C. Contribution of body fatness and adipose tissue distribution to the age variation in plasma steroid hormone concentrations in men: the Heritage Family Study. J Clin Endocrinol Metab 85: 1026-1031, 2000.
9. Field AE, Colditz GA, Willett WC, Longcope C, and McKinlay JB. The relation of smoking, age, relative weight, and dietary intake to serum adrenal steroids, sex hormones, and sex hormone-binding globulin in middle-aged men. J Clin Endocrinol Metab 79: 1310-1316, 1994.
10. Gordon G, Mackow MC, and Levy UR. On the mechanism of interaction of steroids with human glucose 6-phosphate dehydrogenase. Arch Biochem Biophys 318: 25-29, 1995.
11. Gu S, Ripp SL, Prough RA, and Geoghegan TE. Dehydroepiandrosterone affects the expression of multiple genes in rat liver including 11β-hydroxysteroid dehydrogenase type 1: a cDNA array analysis. Mol Pharmacol 63: 722-731, 2003.
12. Hammarstedt A, Jansson PA, Wesslau C, Yang X, and Smith U. Reduced expression of PGC-1 and insulin-signaling molecules in adipose tissue is associated with insulin resistance. Biochem Biophys Res Commun 301: 578-582, 2003.
13. Hermanowski-Vosatka A, Gerhold D, Mundt SS, Loving VA, Lu M, Chen Y, Elbrecht A, Wu M, Doebber T, Kelly L, Milot D, Guo Q, Wang PR, Ippolito M, Chao YS, Wright SD, and Thieringer R. PPARα agonists reduce 11β-hydroxysteroid dehydrogenase type 1 in the liver. Biochem Biophys Res Commun 279: 330-336, 2000.
14. Higashi T, Daifu Y, and Shimada K. Studies on neurosteroids. XIV. Levels of dehydroepiandrosterone sulfate in rat brain and serum determined with newly developed enzyme-linked immunosorbent assay. Steroids 66: 865-874, 2001.
15. Homma M, Onodera T, Hirabatake M, Oka K, Kanazawa M, Miwa T, and Hayashi T. Activation of 11β-hydroxysteroid dehydrogenase by dehydroepiandrosterone sulphate as an anti-hypertensive agent in spontaneously hypertensive rats. J Pharm Pharmacol 50: 1139-1145, 1998.
16. Ishida-Takahashi R, Uotani S, Abe T, Degawa-Yamauchi M, Fukushima T, Fujita N, Sakamaki H, Yamasaki H, Yamaguchi Y, and Eguchi K. Rapid inhibition of leptin signaling by glucocorticoids in vitro and in vivo. J Biol Chem 279: 19658-19664, 2004.
17. Kannisto K, Pietilainen ICH, Ehrenborg E, Rissanen A, Kaprio J, Hamsten A, and Yki-Jarvinen H. Overexpression of 11β-hydroxysteroid dehydrogenase-1 in adipose tissue is associated with acquired obesity and features of insulin resistance: studies in young adult monozygotic twins. J Clin Endocrinol Metab 89: 4414-4421, 2004.
18. Kim MS, Shigenaga J, Moser A, Grunfeld C, and Feingold KR. Suppression of DHEA sulfotransferase (Sult2A1) during the acute-phase response. Am J Physiol Endocrinol Metab 287: E731-E738, 2004.
19. Kobayashi Y, Tagawa N, Muraoka K, Okamoto Y, and Nishida M. Participation of endogenous dehydroepiandrosterone and its sulfate in the pathology of collagen-induced arthritis in mice. Biol Pharm Bull 26: 1596-1599, 2003.
20. Kochan Z and Karbowska J. Dehydroepiandrosterone upregulates resistin gene expression in white adipose tissue. Mol Cell Endocrinol 218: 57-64, 2004.
21. Kopelman PG. Obesity as a medical problem. Nature 404: 635-643, 2000.
22. Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P, Best R, Brown R, Edwards CR, Seckl JR, and Mullins JJ. 11β-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci USA 94: 14924-14929, 1997.
23. Labrie F. Intracrinology. Mol Cell Endocrinol 78: C113-C118, 1991.
24. Laplante M, Sell H, MacNaul KL, Richard D, Berger JP, and Deshaies Y. PPAR-γ activation mediates adipose depot-specific effects on gene expression and lipoprotein lipase activity: mechanisms for modulation of postprandial lipemia and differential adipose accretion. Diabetes 52: 291-299, 2003.
25. Lewitt MS and Brismar K. Gender difference in the leptin response to feeding in peroxisome proliferator-activated receptor-α knockout mice. Int J Obes Relat Metab Disord 26: 1296-1300, 2002.
26. Lindsay RS, Wake DJ, Nair S, Bunt J, Livingstone DE, Permana PA, Tataranni PA, and Walker BR. Subcutaneous adipose 11β-hydroxysteroid dehydrogenase type 1 activity and messenger ribonucleic acid levels are associated with adiposity and insulinemia in Pima Indians and Caucasians. J Clin Endocrinol Metab 88: 2738-2744, 2003.
27. Liu Y, Nakagawa Y, Wang Y, Li R, Li X, Ohzeki T, and Friedman TC. Leptin activation of corticosterone production in hepatocytes may contribute to the reversal of obesity and hyperglycemia in leptin-deficient ob/ob mice. Diabetes 52: 1409-1416, 2003.
28. Livak KJ and Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 25: 402-408, 2001.
29. Livingstone DE and Walker BR. Is 11β-hydroxysteroid dehydrogenase type 1 a therapeutic target? Effects of carbenoxolone in lean and obese Zucker rats. J Pharmacol Exp Ther 305: 167-172, 2003.
30. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, and Flier JS. A transgenic model of visceral obesity and the metabolic syndrome. Science 294: 2166-2170, 2001.
31. Masuzaki H, Yamamoto H, Kenyon CJ, Elmquist JK, Morton NM, Paterson JM, Shinyama H, Sharp MG, Fleming S, Mullins JJ, Seckl JR, and Flier JS. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest 112: 83-90, 2003.
32. McIntosh M, Hausman D, Martin R, and Hausman G. Dehydroepiandrosterone attenuates preadipocyte growth in primary cultures of stromal-vascular cells. Am J Physiol Endocrinol Metab 275: E285-E293, 1998.
33. Morales-Montor J, Newhouse E, Mohamed F, Baghdadi A, and Damian RT. Altered levels of hypothalamic-pituitary-adrenocortical axis hormones in baboons and mice during the course of infection with Schistosoma mansoni. J Infect Dis 183: 313-320, 2001.
34. Morton NM, Holmes MC, Fievet C, Staels B, Tailleux A, Mullins JJ, and Seckl JR. Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11β-hydroxysteroid dehydrogenase type 1 null mice. J Biol Chem 276: 41293-41300, 2001.
35. Morton NM, Paterson JM, Masuzaki H, Holmes MC, Staels B, Fievet C, Walker BR, Flier JS, Mullins JJ, and Seckl JR. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11β-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 53: 931-938, 2004.
36. Napolitano A, Voice MW, Edwards CR, Seckl JR, and Chapman KE. 11β-Hydroxysteroid dehydrogenase 1 in adipocytes: expression is differentiation dependent and hormonally regulated. J Steroid Biochem Mol Biol 64: 251-260, 1998.
37. Odermatt A, Arnold P, Stauffer A, Frey BM, and Frey FJ. The N-terminal anchor sequences of 11β-hydroxysteroid dehydrogenases determine their orientation in the endoplasmic reticulum membrane. J Biol Chem 274: 28762-28770, 1999.
38. + ratio on the activities of hexose-6-phosphate dehydrogenase and glucose-6-phosphate dehydrogenase. Biochim Biophys Acta 662: 318-325, 1981.
39. Ott V, Fasshauer M, Meier B, Dalski A, Kraus D, Gettys TW, Perwitz N, and Klein J. Ciliary neurotrophic factor influences endocrine adipocyte function: inhibition of leptin via PI 3-kinase. Mol Cell Endocrinol 224: 21-27, 2004.
40. Panchapakesan U, Pollock CA, and Chen XM. The effect of high glucose and PPAR-γ agonists on PPAR-γ expression and function in HK-2 cells. Am J Physiol Renal Physiol 287: F528-F534, 2004.
41. Paterson JM, Morton NM, Fievet C, Kenyon CJ, Holmes MC, Staels B, Seckl JR, and Mullins JJ. Metabolic syndrome without obesity: hepatic overexpression of 11β-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci USA 101: 7088-7093, 2004.
42. Paulmyer-Lacroix O, Boullu S, Oliver C, Alessi MC, and Grino M. Expression of the mRNA coding for 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patients: an in situ hybridization study. J Clin Endocrinol Metab 87: 2701-2705, 2002.
43. Perrini S, Natalicchio A, Laviola L, Belsanti G, Montrone C, Cignarelli A, Minielli V, Grano M, De Pergola G, Giorgino R, and Giorgino F. Dehydroepiandrosterone stimulates glucose uptake in human and murine adipocytes by inducing GLUT1 and GLUT4 translocation to the plasma membrane. Diabetes 53: 41-52, 2004.
44. Prusty D, Park BH, Davis KE, and Farmer SR. Activation of MEK/ERK signaling promotes adipogenesis by enhancing peroxisome proliferator-activated receptor γ(PPARγ) and C/EBPα gene expression during the differentiation of 3T3-L1 preadipocytes. J Biol Chem 277: 46226-46232, 2002.
45. Rask E, Walker BR, Soderberg S, Livingstone DE, Eliasson M, Johnson O, Andrew R, and Olsson T. Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11β-hydroxysteroid dehydrogenase type 1 activity. J Clin Endocrinol Metab 87: 3330-3336, 2002.
46. Sandeep TC and Walker BR. Pathophysiology of modulation of local glucocorticoid levels by 11β-hydroxysteroid dehydrogenases. Trends Endocrinol Metab 12: 446-453, 2001.
47. Sandeep TC, Yau JL, MacLullich AM, Noble J, Deary IJ, Walker BR, and Seckl JR. 11β-Hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics. Proc Natl Acad Sci USA 101: 6734-6739, 2004.
48. Schwarte AG and Pashko LL. Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity. Ageing Res Rev 3: 171-187, 2004.
49. Schweizer RA, Atanasov AG, Frey BM, and Odermatt A. A rapid screening assay for inhibitors of 11β-hydroxysteroid dehydrogenases (11β-HSD): flavanone selectively inhibits 11β-HSD1 reductase activity. Mol Cell Endocrinol 212: 41-49, 2003.
50. Sekine O, Nishio Y, Egawa K, Nakamura T, Maegawa H, and Kashiwagi A. Insulin activates CCAAT/enhancer binding proteins and proinflammatory gene expression through the phosphatidylinositol 3-kinase pathway in vascular smooth muscle cells. J Biol Chem 277: 36631-36639, 2002.
51. Stewart PM and Krozowski ZS. 11β-Hydroxysteroid dehydrogenase. Vitam Horm 57: 249-324, 1999.
52. Stulnig TM, Oppermann U, Steffensen KR, Schuster GU, and Gustafsson JA. Liver X receptors downregulate 11β-hydroxysteroid dehydrogenase type 1 expression and activity. Diabetes 51: 2426-2433, 2002.
53. Tchernof A, Despres JP, Belanger A, Dupont A, Prud'homme D, Moorjani S, Lupien PJ, and Labrie F. Reduced testosterone and adrenal C19 steroid levels in obese men. Metabolism 44: 513-519, 1995.
54. Tchernof A and Labrie F. Dehydroepiandrosterone, obesity and cardiovascular disease risk: a review of human studies. Eur J Endocrinol 151: 1-14, 2004.
55. Terauchi Y, Matsui J, Kamon J, Yamauchi T, Kuhota N, Komeda K, Aizawa S, Akanuma Y, Tomita M, and Kadowaki T. Increased serum leptin protects from adiposity despite the increased glucose uptake in white adipose tissue in mice lacking p85α phosphoinositide 3-kinase. Diabetes 53: 2261-2270, 2004.
56. Valsamakis G, McTernan PG, Chetty R, Al Daghri N, Field A, Hanif W, Barnett AH, and Kumar S. Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines. Metabolism 53: 430-434, 2004.
57. Villareal DT and Holloszy JO. Effect of DHEA on abdominal fat and insulin action in elderly women and men: a randomized controlled trial. JAMA 292: 2243-2248, 2004.
58. Whorwood CB, Donovan SJ, Wood PJ, and Phillips DI. Regulation of glucocorticoid receptor α and β isoforms and type I 11β-hydroxysteroid dehydrogenase expression in human skeletal muscle cells: a key role in the pathogenesis of insulin resistance? J Clin Endocrinol Metab 86: 2296-2308, 2001.
59. Williams LJ, Lyons V, MacLeod I, Rajan V, Darlington GJ, Poli V, Seckl JR, and Chapman KE. C/EBP regulates hepatic transcription of 11β-hydroxysteroid dehydrogenase type 1. A novel mechanism for cross-talk between the C/EBP and glucocorticoid signaling pathways. J Biol Chem 275: 30232-30239, 2000,
60. Yoon JC, Puigserver P, Chen G, Donovan J, Wu Z, Rhee J, Adelmant G, Stafford J, Kahn CR, Granner DK, Newgard CB, and Spiegelman BM. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 413: 131-138, 2001.